Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies

Using alpha-synuclein-immunohistochemistry, 27 brains of dementia with Lewy bodies (DLB) were investigated to identify the progression of Lewy pathology including Lewy bodies (LB) and LB-related neurites in the cerebrum. The numbers of alpha-synuclein-positive LB and LB-related neurites were semiquantitatively evaluated in the amygdala, hippocampus, entorhinal cortex, transentorhinal cortex, insular cortex, middle temporal cortex and superior frontal cortex. The results indicated that Lewy pathology within the neuron progresses first in the axonal terminal, subsequently in the cell body and finally in the dendrite, that Lewy pathology in the cerebral cortex progresses first in layers V-VI, subsequently in layer III and finally in layer II, and that Lewy pathology in the cerebrum progresses first in the amygdala, subsequently in the limbic cortex and finally in the neocortex. In addition, Lewy pathology was graded from stage I to stage IV based on the progression of Lewy pathology. The 27 brains examined were classified into 3 brains showing stage I, 11 showing stage II, 7 showing stage III and 6 showing stage IV. Comparing these stages with the pathological subtypes of DLB brains, brains of the subtype showing severe Alzheimer pathology corresponded to brains showing an advanced stage, suggesting that Alzheimer pathology exacerbates Lewy pathology.

[1]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[2]  B. Hyman,et al.  A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50 , 1988, Brain Research.

[3]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[4]  K. Kosaka,et al.  Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease , 1999, Neuroscience Letters.

[5]  E. Ohama,et al.  Parkinson's disease: Distribution of Lewy bodies and monoamine neuron system , 1976, Acta Neuropathologica.

[6]  D. Dickson,et al.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.

[7]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Hirai,et al.  Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy , 2000, Journal of neurology, neurosurgery, and psychiatry.

[9]  T. Iwatsubo,et al.  Degenerative terminals of the perforant pathway are human α-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease , 1998, Neuroscience Letters.

[10]  Masanori Kato,et al.  Clinicopathological multiplicity of dementia with Lewy bodies , 1999 .

[11]  H. Akiyama,et al.  A pathological study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease , 1995 .

[12]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[13]  J. Trojanowski,et al.  Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease , 1994, Acta Neuropathologica.

[14]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[15]  K. Kosaka,et al.  Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease , 2000, Journal of the Neurological Sciences.

[16]  P. Lantos,et al.  Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease , 1996, Neuroscience Letters.

[17]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[18]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[19]  H. Akiyama,et al.  Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies , 2001, Journal of the Neurological Sciences.

[20]  K. Kosaka,et al.  Hippocampal pathology in diffuse Lewy body disease using ubiquitin immunohistochemistry , 1997, Journal of the Neurological Sciences.

[21]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[22]  R. Godwin-Austen,et al.  Diffuse Lewy body disease: clinical features in 15 cases. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[23]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[24]  Kenji Kosaka,et al.  Lewy bodies in cerebral cortex. Report of three cases , 1978, Acta Neuropathologica.

[25]  K Kosaka,et al.  Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? , 1984, Clinical neuropathology.

[26]  H. Akiyama,et al.  Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using α-synuclein-immunohistochemistry , 2000, Neuroscience Letters.